GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » ROE %

Axsome Therapeutics (Axsome Therapeutics) ROE % : -171.39% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Axsome Therapeutics's annualized net income for the quarter that ended in Dec. 2023 was $-394.6 Mil. Axsome Therapeutics's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $230.2 Mil. Therefore, Axsome Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 was -171.39%.

The historical rank and industry rank for Axsome Therapeutics's ROE % or its related term are showing as below:

AXSM' s ROE % Range Over the Past 10 Years
Min: -350.78   Med: -151.19   Max: -56.48
Current: -124.52

During the past 11 years, Axsome Therapeutics's highest ROE % was -56.48%. The lowest was -350.78%. And the median was -151.19%.

AXSM's ROE % is ranked worse than
80.69% of 1362 companies
in the Biotechnology industry
Industry Median: -44.1 vs AXSM: -124.52

Axsome Therapeutics ROE % Historical Data

The historical data trend for Axsome Therapeutics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics ROE % Chart

Axsome Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -76.08 -70.36 -201.51 -298.97 -159.21

Axsome Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -183.55 -40.54 -137.57 -90.75 -171.39

Competitive Comparison of Axsome Therapeutics's ROE %

For the Biotechnology subindustry, Axsome Therapeutics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's ROE % distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's ROE % falls into.



Axsome Therapeutics ROE % Calculation

Axsome Therapeutics's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-239.238/( (109.556+190.977)/ 2 )
=-239.238/150.2665
=-159.21 %

Axsome Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-394.604/( (269.508+190.977)/ 2 )
=-394.604/230.2425
=-171.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Axsome Therapeutics  (NAS:AXSM) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-394.604/230.2425
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-394.604 / 286.12)*(286.12 / 594.5465)*(594.5465 / 230.2425)
=Net Margin %*Asset Turnover*Equity Multiplier
=-137.92 %*0.4812*2.5823
=ROA %*Equity Multiplier
=-66.37 %*2.5823
=-171.39 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-394.604/230.2425
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-394.604 / -395.904) * (-395.904 / -220.268) * (-220.268 / 286.12) * (286.12 / 594.5465) * (594.5465 / 230.2425)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9967 * 1.7974 * -76.98 % * 0.4812 * 2.5823
=-171.39 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Axsome Therapeutics ROE % Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Axsome Therapeutics (Axsome Therapeutics) Business Description

Traded in Other Exchanges
Address
22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.
Executives
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Mark Coleman director 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Hunter R. Murdock officer: General Counsel 22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Roger Jeffs director
Nick Pizzie officer: Chief Financial Officer 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Mark E Saad director C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Herriot Tabuteau director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
Mark L. Jacobson officer: Chief Operating Officer 200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
David C Marek officer: Chief Commercial Officer C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski officer: Chief Financial Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye officer: Chief Medical Officer 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance officer: Vice President, Finance 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc 10 percent owner 630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111

Axsome Therapeutics (Axsome Therapeutics) Headlines